TRX585 is a humanized monoclonal antibody targeting immunoglobulin-like transcript 5 (ILT5). It possesses potent immunomodulatory activity, significantly activating human T cells and upregulating the expression of NKG2D and Fas ligand, thereby enhancing antitumor activity and exhibiting strong cytotoxicity. TRX585 is applicable for research on viral infections and malignant tumors.
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
